CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
NEW YORK, April 04, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York. The presentation is scheduled for Tuesday, April 12, 2016 at 4:20 p.m. EDT.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
Contact: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006
